Lowering LDL‐C through the PCSK9 inhibition pathway has been reported to have both risk‐increasing and risk‐decreasing disease associations, including decreased risk of myocardial infarction7 and decreased cancer risk,8 but also increased risk of type 2 diabetes.9 The gene discussed is PCSK9; the disease is cancer.